ArticleCancer immunology, immunotherapy : CII2022

A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer.

Bangyou Zuo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.